Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
Dave Singh,1 Leonardo M Fabbri,2,3 Stefano Vezzoli,4 Stefano Petruzzelli,4 Alberto Papi2 1Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 2Section of Cardiorespiratory and Internal Medicine, Department of Medical Sciences, University...
Main Authors: | Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-02-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/extrafine-triple-therapy-delays-copd-clinically-important-deterioratio-peer-reviewed-article-COPD |
Similar Items
-
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
by: Vanfleteren L, et al.
Published: (2018-12-01) -
When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment
by: Cheng WC, et al.
Published: (2020-12-01) -
Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
by: Tariq SM, et al.
Published: (2017-06-01) -
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
by: Abdul Aziz MI, et al.
Published: (2018-10-01) -
Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
by: Akira Koarai, et al.
Published: (2021-06-01)